Fluoxetine may worsen hyperoxia-induced lung damage in neonatal rats

Histology and Histopathology

Volumn 27, Issue 12, 2012, Pages 1599-1610

  Porzionato, Andrea ^a   Zaramella, Patrizia ^a   Macchi, Veronica ^a   Grisafi, Davide ^a   Salmaso, Roberto ^a   Baraldi, Maura ^a   Fornaro, Enrica ^a   Tassone, Evelyn ^a   Masola, Valentina ^a   Onisto, Maurizio ^a   Chiandetti, Lino ^a   De Caro, Raffaele ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bronchopulmonar dysplasia; Matrix metalloproteinases; VEGF

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; GELATINASE A; MACROPHAGE ELASTASE; MESSENGER RNA; MMP2 PROTEIN, RAT; PGP9.5 PROTEIN, RAT; SEROTONIN UPTAKE INHIBITOR; UBIQUITIN THIOLESTERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL; ARTICLE; BREATHING MUSCLE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; HUMAN; HYPEROXIA; LUNG DYSPLASIA; LUNG INJURY; METABOLISM; NEUROSECRETORY CELL; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREGNANCY; RAT; SPRAGUE DAWLEY RAT; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BASE SEQUENCE; BRONCHOPULMONARY DYSPLASIA; DISEASE MODELS, ANIMAL; FEMALE; FLUOXETINE; HUMANS; HYPEROXIA; INFANT, NEWBORN; LUNG INJURY; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; NEUROENDOCRINE CELLS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY MUSCLES; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; UBIQUITIN THIOLESTERASE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 84871073361     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Allaman I., Fiumelli H., Magistretti P.J. and Martin J.L. (2011). Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 216, 75-84.
2. Balasubramaniam V., Mervis C.F., Maxey A.M., Markham N.E. and Abman S.H. (2007). Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1073-L1084.
3. Bancalari E., Claure N. and Sosenko I.R. (2003). Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin. Neonatol. 8, 63-71.
4. 2 exposure enhances vascular and airway smooth muscle contraction in the newborn but not adult rat. J. Appl. Physiol. 94, 2303-2312.
5. Bhatt A.J., Pryhuber G.S., Huyck H., Watkins R.H., Metlay L.A. and Maniscalco W.M. (2001). Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 164, 1971-1980.
6. Buckley S. and Warburton D. (2002). Dynamics of metalloproteinase-2 and -9, TGF-beta, and uPA activities during normoxic vs. hyperoxic alveolarization. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L747-754.
7. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L. and Mitchell AA. (2006). Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354, 579-587.
8. Cooney T.P. and Thurlbeck W.M. (1982a). The radial alveolar count method of Emery and Mithal:a reappraisal 1--postnatal lung growth. Thorax 37, 572-579.
9. Cooney T.P. and Thurlbeck W.M. (1982b). The radial alveolar count method of Emery and Mithal:a reappraisal 2--intrauterine and early postnatal lung growth. Thorax 37, 580-583.
10. Cullen A., Van Marter L.J., Allred E.N., Moore M., Parad R.B. and Sunday M.E. (2002). Urine bombesin-like peptide elevation precedes clinical evidence of bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 165, 1093-1097.
11. Cutz E., Gillan J.E. and Bryan A.C. (1985). Neuroendocrine cells in the developing human lung: morphologic and functional considerations. Pediatr. Pulmonol. 1, S21-S29.
12. Danan C., Jarreau P.H., Franco M.L., Dassieu G., Grillon C., Abd Alsamad I., Lafuma C., Harf A. and Delacourt C. (2002). Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L1086-L1093.
13. Dauger S., Ferkdadji L., Saumon G., Vardon G., Peuchmaur M., Gaultier C. and Gallego J. (2003). Neonatal exposure to 65% oxygen durably impairs lung architecture and breathing pattern in adult mice. Chest 123, 530-538.
14. Dwivedi A., Slater S.C. and George S.J. (2009). MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc. Res. 81, 178-186.
15. Emery J.L. and Mithal A. (1960). The number of alveoli in the terminal respiratory unit of man during late intrauterine life and childhood. Arch. Dis. Child. 35, 544-547.
16. Fabris V.E., Pato M.D. and Belik J. (2001). Progressive lung and cardiac changes associated with pulmonary hypertension in the fetal rat. Pediatr. Pulmonol. 31, 344-353.
17. Fleschler R. and Peskin M.F. (2008). Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: a review. MCN Am. J. Matern. Child Nurs. 33, 355-361.
18. Fornaro E., Li D., Pan J. and Belik J. (2007). Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am. J. Respir. Crit. Care Med. 176, 1035-1040.
19. Fulton R.M., Hutchinson E.C. and Jones A.M. (1952). Ventricular weight in cardiac hypertrophy. Br. Heart J. 14, 413-420.
20. Greene J., Banasr M., Lee B., Warner-Schmidt J. and Duman R.S. (2009). Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 34, 2459-2468.
21. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., Hamon M., Adnot S. and Eddahibi S. (2005). Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111, 2812-2819.
22. Hosford G.E. and Olson D.M. (2003). Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L161-L168.
23. Hosford G.E., Fang X. and Olson D.M. (2004). Hyperoxia decreases matrix metalloproteinase-9 and increases tissue inhibitor of matrix metalloproteinase-1 protein in the newborn rat lung: association with arrested alveolarization. Pediatr. Res. 56, 26-34.
24. Jobe A.H. and Bancalari E. (2001). Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723-1729.
25. Johnson S. and Knox A. (1999). Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am. J. Physiol. 277, L1109-L1117.
26. Johnson D.E., Kulik T.J., Lock J.E., Elde R.P. and Thompson T.R. (1985). Bombesin-, calcitonin-, and serotonin-immunoreactive pulmonary neuroendocrine cells in acute and chronic neonatal lung disease. Pediatr. Pulmonol. 1, S13-20.
27. Jones R., Zapol W.M. and Reid L. (1984). Pulmonary artery remodeling and pulmonary hypertension after exposure to hyperoxia for 7 days. A morphometric and hemodynamic study. Am. J. Pathol. 117, 273-285.
28. Kawut S.M., Horn E.M., Berekashvili K.K., Lederer D.J., Widlitz A.C., Rosenzweig E.B. and Barst R.J. (2006). Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm. Pharmacol. Ther. 19, 370-374.
29. Koppel R., Han R.N., Cox D., Tanswell A.K. and Rabinovitch M. (1994). Alpha 1-antitrypsin protects neonatal rats from pulmonary vascular and parenchymal effects of oxygen toxicity. Pediatr. Res. 36, 763-770.
30. Kubera M., Grygier B., Arteta B., Urbańska K., Basta-Kaim A., Budziszewska B., Leśkiewicz M., Kołaczkowska E., Maes M., Szczepanik M., Majewska M. and Lasoń W. (2009). Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol. Rep. 61, 1113-1126.
31. Lassus P., Ristimäki A., Ylikorkala O., Viinikka L. and Andersson S. (1999). Vascular endothelial growth factor in human preterm lung. Am. J. Respir. Crit. Care Med. 159, 1429-1433.
32. Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.R. Jr. and Vazquez D.M. (2005). Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a metaanalysis. J. Perinatol. 25, 595-604.
33. Li D., Zhang C., Song F., Lubenec I., Tian Y. and Song Q.H. (2009). VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc. Res. 77, 134-142.
34. Li X.Q., Wang H.M., Yang C.G., Zhang X.H., Han D.D. and Wang H.L. (2011). Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol. Sin. 32, 217-222.
35. Liu X., Smith B.J., Chen C., Callegari E., Becker S.L., Chen X., Cianfrogna J., Doran A.C., Doran S.D., Gibbs J.P., Hosea N., Liu J., Nelson F.R., Szewc M.A. and Van Deusen J. (2005). Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther. 313, 1254-1262.
36. Marcos E., Adnot S., Pham M.H., Nosjean A., Raffestin B., Hamon M. and Eddahibi S. (2003). Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 168, 487-493.
37. Nishihara-Fujihara M., Shoji S., Maeda I., Shimoda T., Nishima S. and Okamoto K. (2010). Involvement of fibronectin and matrix metalloproteinases in airway smooth muscle cell migration for the process of airway remodeling. Allergol. Int. 59, 267-275.
38. Nocito A., Dahm F., Jochum W., Jang J.H., Georgiev P., Bader M., Graf R. and Clavien P.A. (2008). Serotonin regulates macrophagemediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 68, 5152-5158.
39. Porzionato A., Macchi V., Parenti A., Matturri L. and De Caro R. (2008). Peripheral chemoreceptors: postnatal development and cytochemical findings in Sudden Infant Death Syndrome. Histol. Histopathol. 23, 351-365.
40. Remesal A., Pedraz C., San Feliciano L. and Ludeña D. (2009). Pulmonary expression of vascular endothelial growth factor (VEGF) and alveolar septation in a newborn rat model exposed to acute hypoxia and recovered under conditions of air or hyperoxia. Histol. Histopathol. 24, 325-330.
41. Riksen E.A., Stunes A.K., Kalvik A., Gustafsson B.I., Snead M.L., Syversen U., Lyngstadaas S.P. and Reseland J.E. (2010). Serotonin and fluoxetine receptors are expressed in enamel organs and LS8 cells and modulate gene expression in LS8 cells. Eur. J. Oral. Sci. 118, 566-573.
42. Shenberger J.S., Shew R.L. and Johnson D.E. (1997). Hyperoxiainduced airway remodeling and pulmonary neuroendocrine cell hyperplasia in the weanling rat. Pediatr. Res. 42, 539-544.
43. Slongo M.L., Zampieri M. and Onisto M. (2002). Expression of matrix metalloproteases (MMP-2, MT1 -MMP) and their tissue inhibitor (TIMP-2) by rat sertoli cells in culture: implications for spermatogenesis. Biol. Chem. 383, 235-239.
44. Stevens J.C. and Wrighton S.A. (1993). Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 266, 964-971.
45. Thebaud B. and Abman S.H. (2007). Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am. J. Respir. Crit. Care Med. 175, 978-985.
46. Wagenaar G.T., ter Horst S.A., van Gastelen M.A., Leijser L.M., Mauad T., van der Velden P.A., de Heer E., Hiemstra P.S., Poorthuis B.J. and Walther F.J. (2004). Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic. Biol. Med. 36, 782-801.
47. Wang Z., Kong L., Kang J., Vaughn D.M., Bush G.D., Walding A.L., Grigorian A.A., Robinson J.S. Jr. and Nakayama D.K. (2011). Interleukin-lbeta induces migration of rat arterial smooth muscle cells through a mechanism involving increased matrix metalloproteinase-2 activity. J. Surg. Res. 169, 328-336.
48. Warner-Schmidt J.L. and Duman R.S. (2007). VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. USA 104, 4647-4652.
49. Weissman A.M., Levy B.T., Hartz A.J., Bentler S., Donohue M., Ellingrod V.L. and Wisner K.L. (2004). Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am. J. Psychiat.161, 1066-1078.
50. Yi M., Jankov R.P., Belcastro R., Humes D., Copland I., Shek S., Sweezey N.B., Post M., Albertine K.H., Auten R.L. and Tanswell A.K. (2004). Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. Am. J. Respir. Crit. Care Med. 170, 1188-1196.
51. Zhai F.G., Zhang X.H. and Wang H.L. (2009). Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin. Exp. Pharmacol. Physiol. 36, 850-856.